The global pen needles market size reached US$ 3.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2028, exhibiting a growth rate (CAGR) of 14.4% during 2023-2028.
Pen needles are disposable hollow needles used in pen injectors for delivering pharmaceutical drugs in the subcutaneous tissues of the body. The needle is fixed in the plastic hub of the medical injector pen and consists of plastic caps and individual wrapping for enhanced security and sterilization. Pen needles are manufactured using electro-polishing techniques to achieve smooth, fine and thin point tips for convenient penetration. They are available in a wide variety of gauge sizes and lengths and are majorly used by diabetic patients that require multiple dosages of insulin injections every day. In comparison to the traditionally used syringes and vials, pen needles are highly cost-effective, convenient to use, portable and do not require refrigeration.
Pen Needles Market Trends:
The increasing prevalence of diabetes mellitus (DM) and other chronic medical disorders, such as osteoporosis, cardiovascular disease (CVD) and multiple sclerosis, is one of the key factors driving the growth of the market. The treatment of these ailments require multidrug regimen that involves daily or weekly administration of medicinal drugs with injector pens. Moreover, the rising geriatric population, which is more susceptible to chronic ailments is contributing to the growth of the market. Insulin pens provide a reliable, accurate and simplified dosing solution to the elderly patients and facilitate self-administration. Additionally, various product innovations, such as the development of ultra-thin and short-length needles with improved drug delivery systems, are acting as other growth-inducing factors. The traditionally used needles were difficult to use during self-dosage and caused more pain and discomfort to the patients. Other factors, including the increasing healthcare expenditure capacities of the masses, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pen needles market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, needle length, therapy, mode of purchase and end user.
Breakup by Type:
Standard Pen Needles
Safety Pen Needles
Breakup by Needle Length:
4mm
5mm
6mm
8mm
10mm
12mm
Breakup by Therapy:
Insulin
GLP-1
Growth Hormones
Breakup by Mode of Purchase:
Retail
Non-Retail
Breakup by End User:
Hospitals and Clinics
Home Healthcare
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare) and Ultimed Inc.
Report Coverage:
Report Features
Details
Base Year of the Analysis
2022
Historical Period
2017-2022
Forecast Period
2023-2028
Units
US$ Billion
Segment Coverage
Type, Needle Length, Therapy, Mode of Purchase, End User, Region
Region Covered
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered
A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare) and Ultimed Inc.
Customization Scope
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
10-12 Weeks
Delivery Format
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global pen needles market was valued at US$ 3.3 Billion in 2022.
We expect the global pen needles market to exhibit a CAGR of 14.4% during 2023-2028.
The rising prevalence of chronic disorders, such as Diabetes Mellitus (DM), that require daily or
weekly administration of medicinal drugs, is primarily driving the global pen needles market.
The sudden outbreak of the COVID-19 pandemic has led to rising utilization of pen needles for self- administration of drugs, particularly among patients suffering from medical ailments, to avoid coronavirus infection upon hospital or clinic visits.
Based on the type, the global pen needles market can be segregated into standard pen needles and safety pen needles. Currently, standard pen needles account for the largest market share.
Based on the needle length, the global pen needles market has been divided into 4mm, 5mm, 6mm, 8mm, 10mm, and 12mm. Among these, 8mm long needles currently exhibit a clear dominance in the market.
Based on the therapy, the global pen needles market can be bifurcated into insulin, GLP-1, and
growth hormones, where insulin therapy holds the majority of the total market share.
Based on the mode of purchase, the global pen needles market has been categorized into retail and non-retail. Currently, retail purchase exhibits a clear dominance in the market.
Based on the end user, the global pen needles market can be segmented into hospitals and clinics, home healthcare, and others. Among these, hospitals and clinics currently represent the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where Europe currently dominates the global market.
Some of the major players in the global pen needles market include A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare), and Ultimed Inc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
This site uses cookies (including third-party cookies) to record user’s preferences which help us to enhance our services. For further information review our Privacy Policy.
This site uses cookies to improve user experience.Privacy Policy.